Bright minds biosciences inc.DRUG.US Overview

US StockHealthcare

(No presentation for DRUG)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

DRUG Overall Performance

DRUG AI Analysis & Strategy

DRUG Recent Performance

5.34%

Bright minds biosciences inc.

0.81%

Avg of Sector

-1.14%

S&P500

DRUG PowerScanner

DRUG Key Information

DRUG Valuation Metrics

DRUG Earnings Table

DRUG Profile

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.